Salisbury Foundation Trust

FOI_6025

Internal Reference Number: FOI_6025

Date Request Received: 04/02/2021 11:33:53

Date Request Replied To: 10/02/2021 15:15:28

This response was sent via: By Email

Request Summary: incidence and treatment of breast cancer

Request Category: Private Individuals

 
Question Number 1:
I am researching the incidence and treatment of breast cancer. Could you please provide the number of patients that you have treated in the past three months with the following:
• Abemaciclib + Anastrozole/Exemestane/Letrozole
• Abemaciclib + Fulvestrant
• Alpelisib + Fulvestrant
• Atezolizumab
• Bevacizumab
• Eribulin
• Everolimus + Exemestane
• Fulvestrant as a single agent
• Gemcitabine + Paclitaxel
• Lapatinib
• Neratinib
• Olaparib
• Palbociclib + Anastrozole/Exemestane/Letrozole
• Palbociclib + Fulvestrant
• Pertuzumab + Trastuzumab + Docetaxel
• Ribociclib + Anastrozole/Exemestane/Letrozole
• Ribociclib + Fulvestrant
• Talazoparib
• Transtuzumab + Paclitaxel
• Transtuzumab as a single agent
• Trastuzumab emtansine
• Any other active systemic anti-cancer therapy
 
Answer To Question 1:
Please see attached refusal notice explaining why the Trust will not be answering this FOI.
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2021 Salisbury NHS Foundation Trust
Trust Values